Prospector
Profile
3-13-003
|
| |
| Cerus Corporation |
NAICS |
541710 |
| 2411 Stanwell Dr.,
Concord, CA 94520 |
Description |
Biotechnology |
| (925) 288-6000 |
Employees |
111 |
| http://www.cerus.com |
Revenue |
(mil) |
11.0400 |
| |
Income |
(mil) |
-45.3000 |
| |
Assets |
(mil) |
78.2100 |
| |
Liability |
(mil) |
18.3200 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Cerus Corporation reported a net loss of $45.30 million on total revenue of $11.04 million for the year ended December 31, 2007, compared with a net loss of $4.78 million on total revenue of $30.31 million in the prior year. At December 31, 2007, the Company's balance sheet showed an accumulated deficit of $356.73 million. The Company also used cash for operating activities of $14.68 million during 2006, compared to $37.40 million last year.
|
| |
|
Intellectual Property:
As of December 31, 2007, the Company owned approximately 30 issued or allowed United States patents and approximately 65 issued or allowed foreign patents related to the INTERCEPT Blood System. The INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. In addition, the Company has pending United States patent applications and has filed corresponding patent applications under the Patent Cooperation Treaty. The Company has a license from Fenwal to United States and foreign patents relating to the INTERCEPT Blood System. [SEC 10-K 02-27-08]
|
| |
|
Description:
Cerus Corporation, focuses on the development and commercialization of the INTERCEPT Blood System.
|
| |
|
Officers:
Claes Glassell (Pres. & CEO); Laurence M. Corash, M.D. (SVP & Chief Medical Officer); William J. Dawson (VP-Finance & CFO); Howard G. Ervin (VP-Legal Affairs);
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock Symbol CERS; NasdaqGM; 32.2 million common shares outstanding as of February 8, 2008.
|
| |
| |
| |
| return to main page |
